Eastern Bank Trims Holdings in Zoetis Inc. $ZTS

Eastern Bank reduced its stake in Zoetis Inc. (NYSE:ZTS) by 53.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 10,336 shares of the company’s stock after selling 11,639 shares during the quarter. Eastern Bank’s holdings in Zoetis were worth $1,300,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC raised its position in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the third quarter worth $31,000. Holos Integrated Wealth LLC purchased a new position in shares of Zoetis during the fourth quarter worth $32,000. Finally, Financial Consulate Inc. acquired a new stake in shares of Zoetis in the third quarter valued at $39,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.1%

NYSE:ZTS opened at $113.48 on Monday. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The firm has a market cap of $47.90 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 1.73 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a fifty day moving average price of $123.39 and a 200 day moving average price of $129.03.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Wall Street Analyst Weigh In

ZTS has been the topic of several research analyst reports. Morgan Stanley set a $160.00 price objective on Zoetis in a report on Thursday, December 18th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Bank of America boosted their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.